DOCSLIB.ORG

Supp Material.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supp Material.Pdf Supplemental Table I. Genes concomitantly modulated by activated Notch1 in mouse and human primary keratinocytes. Genes up-regulated by Notch1 both in human and in mouse keratinocytes M access. # Hu access. # NIC/GFP M NIC/GFP Hu Description X60367 M11433 20.72 4.23 Retinol binding protein 1 AW049647 AF070523 2.28 8.10 X99921 AI541308 3.46 6.32 S100 calcium-binding protein A13 M28383 U05596 6.02 3.38 Solute carrier family 4 (anion exchanger), member 3 U14135 M14648 2.96 5.91 Integrin alpha V (Cd51) X99921 AI541308 2.06 6.32 S100 calcium-binding protein A13 D88533 D82326 3.58 4.48 NBAT M60057 J03802 3.24 4.55 Parathyroid hormone- like peptide AJ237939 U43185 2.84 4.13 partial STAT5B gene, exons 6-9 U61085 X91220 2.11 4.62 thiazide-sensitive Na-Cl cotransporter mRNA AA882416 D87127 2.54 3.88 L22545 AF018081 2.48 3.79 Procollagen, type XVIII, alpha 1 AW121732 L78833 2.78 3.23 AW121732 L78833 2.78 3.16 U90435 AI807620 2.20 3.68 flotillin AB022022 AL031177 2.07 3.61 gankyrin X14943 Z21488 3.57 2.07 Contactin 1 AJ223855 AJ010063 2.14 3.20 telethonin AW060546 X70944 2.10 3.22 U14135 M14648 2.96 2.20 Integrin alpha V (Cd51) U12961 M81600 2.92 2.20 NAD(P)H menadione oxidoreductase 1, dioxin inducible X98207 U50079 2.15 2.91 histone deacetylase X07888 M11058 2.90 2.15 HMGCR gene for 3- hydroxy-3-methylglutaryl coenzyme A reductase L18888 L10284 2.45 2.54 Calnexin X98207 D50405 2.15 2.79 histone deacetylase AW046032 M62424 2.30 2.62 X13460 Y00097 2.67 2.24 Annexin VI, p68 AC002397 U72511 2.16 2.61 U12961 M81600 2.56 2.20 NAD(P)H menadione oxidoreductase 1, dioxin inducible Z68618 M95787 2.26 2.30 Transgelin AA615429 AB020631 2.17 2.38 AF037312 L78207 2.03 2.37 AC002397 U47924 2.16 2.21 U43541 X79683 2.04 2.26 Laminin, beta 2 Genes down-regulated by Notch1 both in human and in mouse keratinocytes M access. # Hu access. # NIC/GFP M NIC/GFP Hu Description L00039 V00568 0.20 0.06 Myelocytomatosis oncogene Y12881 Z14000 0.10 0.18 transcription repressor Ring1A AB010152 Y16961 0.19 0.10 p73H AF064088 S81439 0.30 0.00 transcription factor GIF U17291 M36711 0.25 0.06 transcription factor AP-2 (AP-2) gene AF061260 AB017563 0.28 0.06 immunosuperfamily protein Bl2 AF064088 AF050110 0.30 0.04 transcription factor GIF AF064088 S81439 0.40 0.00 transcription factor GIF J04103 AF017257 0.38 0.03 E26 avian leukemia oncogene 2 Y12881 AL031228 0.10 0.31 transcription repressor Ring1A AI852829 AL022238 0.37 0.04 M20658 M27492 0.37 0.05 Interleukin 1 receptor AI846938 AF055001 0.34 0.08 AW123880 Z93930 0.38 0.04 AF064088 AF050110 0.40 0.04 transcription factor GIF AI132380 AB023187 0.35 0.09 AB006758 AB006755 0.21 0.24 Pcdh7 BH-protocadherin-a AA110657 U42390 0.33 0.12 AW046449 D82351 0.32 0.14 L00039 V00568 0.20 0.26 Myelocytomatosis oncogene M32490 Y11307 0.29 0.17 Insulin-like growth factor binding protein 10 AJ011033 AF054506 0.09 0.38 kcc2 gene M88242 U04636 0.01 0.46 Mouse glucocortoid-regulated inflammatory prostaglandin G U67187 L13463 0.22 0.25 G protein signaling regulator RGS2 (rgs2) U20344 U70663 0.33 0.16 Gut enriched Kruppel-like factor AF083464 AL096744 0.35 0.14 DNA polymerase zeta catalytic subunit AW125858 U14391 0.28 0.22 X96639 S79639 0.39 0.12 Exostoses (multiple) 1 AW120868 AL080156 0.48 0.03 AW046563 M65254 0.40 0.12 AF061260 AB017563 0.46 0.06 immunosuperfamily protein Bl2 AJ010045 AJ010046 0.47 0.05 Rho guanine nucleotide- exchange factor AW045443 U49020 0.38 0.15 U12763 AL022310 0.24 0.30 Tax-transcriptionally activated glycoprotein 1 ligand X54149 N95168 0.11 0.43 Myeloid differentiation primary response gene 118 X01026 J02843 0.13 0.41 Mouse fragment for repetitive element B2 AW123880 Z93930 0.38 0.17 AF100956 Z14000 0.37 0.18 major histocompatibility locus class II region; Fas-binding protein Daxx (DAXX) gene AF100956 AA808961 0.37 0.19 major histocompatibility locus class II region; Fas-binding protein Daxx (DAXX) gene L26479 J04617 0.29 0.30 Eukaryotic translation elongation factor 1 alpha 2 M26071 J02931 0.35 0.25 Coagulation factor III X75427 X17033 0.41 0.20 Integrin alpha 2 (Cd49b) X65138 L36645 0.43 0.18 Eph receptor A4 X60676 D83174 0.46 0.16 HSP47 M73696 L20859 0.45 0.17 Murine Glvr-1 U37501 AB011105 0.39 0.23 Laminin U77615 W29036 0.24 0.40 Cone-rod homeobox containing gene AF005886 D50310 0.31 0.34 cyclin I AF020200 X59841 0.38 0.26 transcription factor PBX3b (PBX3b) AA611766 D14520 0.28 0.37 AF031035 AF098462 0.20 0.45 stanniocalcin (Stc2) Y08701 Y09703 0.33 0.32 Pinin protein AF100956 D42040 0.37 0.28 major histocompatibility locus class II region; Fas-binding protein Daxx (DAXX) gene U13174 U30246 0.21 0.44 Solute carrier family 12 AF020200 X59841 0.39 0.26 transcription factor PBX3b (PBX3b) L26479 W28170 0.29 0.37 Eukaryotic translation elongation factor 1 alpha 2 AB006036 U88666 0.45 0.22 Serine X60664 M26061 0.31 0.36 CGMP phosphodiesterase alpha AF100956 AF006041 0.37 0.31 major histocompatibility locus class II region; Fas-binding protein Daxx (DAXX) gene AI845578 AJ224326 0.42 0.26 AI846890 Z75331 0.40 0.29 AI843466 AI557272 0.39 0.30 D83966 U12128 0.34 0.36 Protein tyrosine phosphatase AF109905 AJ012008 0.35 0.36 major histocompatibility locus class III regions Hsc70t gene AB025966 AB002310 0.39 0.33 KIAA312p D21831 AL031228 0.41 0.31 Retinoid X receptor beta AI843738 U50383 0.39 0.34 AI852829 AL022238 0.37 0.35 AW123479 D30612 0.33 0.40 AW124113 AA135683 0.32 0.42 AI842675 M80254 0.34 0.40 AB021961 X02469 0.34 0.41 mutant p53 AF017085 AF015553 0.42 0.34 BAP-135 homolog (Diws1t) AW121185 AB002323 0.42 0.33 D90374 M80261 0.50 0.27 Mouse APEX nuclease AB021961 X02469 0.36 0.41 mutant p53 AF004108 U40391 0.29 0.48 arylalkylamine N- acetyltransferase AF005886 D50310 0.44 0.34 cyclin I M60474 D10522 0.40 0.38 Myristoylated alanine rich protein kinase C substrate AF007552 AF007551 0.28 0.49 Bet1p homolog (mbet1) AI839918 U09510 0.39 0.40 AI839918 U09510 0.39 0.40 L10385 L10386 0.34 0.46 transglutaminase E (TGASE3) AF017085 U77948 0.42 0.38 BAP-135 homolog (Diws1t) AI182203 AF054506 0.42 0.38 AI197161 U88629 0.39 0.42 AI845935 AL031282 0.37 0.44 AF109905 AJ012008 0.47 0.36 major histocompatibility locus class III regions Hsc70t gene AW125800 AB028986 0.44 0.39 AW047978 AF020760 0.47 0.37 U32107 L02870 0.49 0.36 Procollagen AF085192 AF070616 0.43 0.42 neural visinin-like protein 3 (NVP- 3) AI117848 U15128 0.47 0.39 AF100956 U41068 0.37 0.50 major histocompatibility locus class II region; Fas-binding protein Daxx (DAXX) gene AW122255 AB007931 0.49 0.40 AF056187 X04434 0.48 0.40 insulin-like growth factor I receptor U29055 AL031282 0.46 0.44 Guanine nucleotide binding protein AA867340 D38521 0.48 0.43 AI854811 X55504 0.44 0.47 AI849620 M63180 0.48 0.44 AW050034 D28476 0.42 0.50 AB006036 U88666 0.45 0.47 Serine M31690 X01630 0.46 0.49 Arginosuccinate synthetase 1 AB005132 D45906 0.49 0.46 LIM motif-containing protein kinase 2 U40796 L20046 0.49 0.46 Xeroderma pigmentosum J04627 X16396 0.47 0.50 Mouse NAD-dependent methylenetetrahydrofolate dehydrogenase- methenyltetrahydrofolate cyclohydrolase RNA was prepared from primary mouse and human keratinocytes infected with the Ad- NIC versus Ad-GFP adenoviruses and used for cRNA probe preparation and hybridization to Affymetrix U74A and U95A gene chips, respectively. Only positive flurorescence intensity values were considered. Human and mouse gene average intensities were scaled as described (Tusher et al. 2001) and genes with scaled intensity difference > 500 and changes in gene expression of >2 folds (in NIC vs GFP comparisons) in both duplicates of each hybridization reaction were considered as significant. Shown are the accession numbers for both mouse and human genes as well as gene description whenever known. The relative expression levels of genes in Ad-NIC versus Ad-GFP – infected cells of both mouse (NIC/GFP M) and human (NIC/GFP Hu) origin is indicated. Supplemental Table II. Selective Notch control of interferon responsive genes. Accession Function Gene GFP N1 N1/GFP Interferons and related cytokines NM_002416 chemokine (C-X-C motif) ligand 9 CXCL9 40.2 68.3 1.7 NM_001565 chemokine (C-X-C motif) ligand 10 CXCL10 47.5 52.3 1.1 NM_000600 interleukin 6 (interferon, beta 2) IL6 66.8 80.2 1.2 NM_001562 interleukin 18 (interferon-gamma-inducing factor) IL18 959.3 383.7 0.4 NM_002172 interferon, alpha 14 IFNA14 48.3 62.8 1.3 NM_021057 interferon, alpha 7 IFNA7 27.5 24.8 0.9 NM_002171 interferon, alpha 10 IFNA10 24.7 19.8 0.8 NM_006900 interferon, alpha 13 IFNA13 33.0 29.7 0.9 AF030514 chemokine (C-X-C motif) ligand 11 CXCL11 29.4 8.8 0.3 M29383 interferon, gamma IFNG 23.2 20.9 0.9 M38289 interferon, alpha 17 IFNA17 111.1 133.3 1.2 NM_002169 interferon, alpha 5 IFNA5 8.4 33.6 4.0 NM_021068 interferon, alpha 4 IFNA4 39.9 35.9 0.9 NM_004847 allograft inflammatory factor 1 AIF1 32.6 71.7 2.2 Interferon receptors NM_005534 interferon gamma receptor 2 (interferon gamma transducer 1) IFNGR2 1567.2 1880.6 1.2 NM_000416 interferon gamma receptor 1 IFNGR1 756.1 982.9 1.3 NM_000629 interferon (alpha, beta and omega) receptor 1 IFNAR1 50.3 40.2 0.8 NM_000874 interferon (alpha, beta and omega) receptor 2 IFNAR2 99.7 199.4 2.0 L41944 interferon (alpha, beta and omega) receptor 2 IFNAR2 29.9 44.9 1.5 AF056979 interferon gamma receptor 1 IFNGR1 280.7 561.4 2.0 Interferon regulators NM_002534 2',5'-oligoadenylate synthetase 1, 40/46kDa OAS1 314.8 157.4 0.5 NM_016817 2'-5'-oligoadenylate synthetase 2, 69/71kDa OAS2 765.1 382.6 0.5 NM_006187 2'-5'-oligoadenylate synthetase 3, 100kDa OAS3 514.1 308.5 0.6 AF063612 2'-5'-oligoadenylate synthetase-like OASL 142.4 128.2 0.9 BC002704 signal
Load more

Recommended publications
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • Jimmunol.0903453.Full.Pdf
    Antiviral Response Dictated by Choreographed Cascade of Transcription Factors This information is current as Elena Zaslavsky, Uri Hershberg, Jeremy Seto, Alissa M. of October 2, 2021. Pham, Susanna Marquez, Jamie L. Duke, James G. Wetmur, Benjamin R. tenOever, Stuart C. Sealfon and Steven H. Kleinstein J Immunol published online 17 February 2010 http://www.jimmunol.org/content/early/2010/02/17/jimmun ol.0903453 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/02/15/jimmunol.090345 Material 3.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 17, 2010, doi:10.4049/jimmunol.0903453 The Journal of Immunology Antiviral Response Dictated by Choreographed Cascade of Transcription Factors Elena Zaslavsky,*,†,1 Uri Hershberg,‡,1 Jeremy Seto,*,† Alissa M. Pham,x Susanna Marquez,‡ Jamie L. Duke,{ James G. Wetmur,x Benjamin R. tenOever,x Stuart C. Sealfon,*,† and Steven H.
    [Show full text]
  • Diverse Functional Autoantibodies in Patients with COVID-19
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.10.20247205; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Diverse Functional Autoantibodies in Patients with COVID-19 Eric Y. Wang1,*, Tianyang Mao1,*, Jon Klein1,*, Yile Dai1,*, John D. Huck1, Feimei Liu1, Neil S. Zheng1, Ting Zhou1, Benjamin Israelow1, Patrick Wong1, Carolina Lucas1, Julio Silva1, Ji Eun Oh1, Eric Song1, Emily S. Perotti1, Suzanne Fischer1, Melissa Campbell5, John B. Fournier5, Anne L. Wyllie3, Chantal B. F. Vogels3, Isabel M. Ott3, Chaney C. Kalinich3, Mary E. Petrone3, Anne E. Watkins3, Yale IMPACT Team¶, Charles Dela Cruz4, Shelli F. Farhadian5, Wade L. Schulz6,7, Nathan D. Grubaugh3, Albert I. Ko3,5, Akiko Iwasaki1,3,8,#, Aaron M. Ring1,2,# 1 Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA 2 Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA 3 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA 4 Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale School of Medicine, New Haven, CT, USA 5 Department of Internal Medicine (Infectious Diseases), Yale School of Medicine, New Haven, CT, USA 6 Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA 7 Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA 8 Howard Hughes Medical Institute, Chevy Chase, MD, USA * These authors contributed equally to this work ¶ A list of authors and their affiliations appears at the end of the paper # Correspondence: [email protected] (A.M.R.); [email protected] (A.I.) 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
    Author Manuscript Published OnlineFirst on April 4, 2018; DOI: 10.1158/1078-0432.CCR-17-3008 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance Zhenqing Ye1; Haidong Dong2,3; Ying Li1; Tao Ma1,4; Haojie Huang4; Hon-Sing Leong4; Jeanette Eckel-Passow1; Jean-Pierre A. Kocher1; Han Liang5; LiguoWang1,4,* 1Division of Biomedical Statistics and Informatics, Department of Health Sciences, Mayo Clinic, Rochester, Minnesota 55905, United States of America 2Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, United States of America 3Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, United States of America 4Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, United States of America 5Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States of America Running title: Pervasive Deletion of Interferon/Defensin in Human Cancers Keywords: Homozygous deletion, Type-I interferon, Defensin, immunotherapy resistance, cancer * Correspondence to: Liguo Wang, Ph.D. Associate Professor Division of Biomedical Statistics and Informatics, Mayo Clinic 200 1st St SW Rochester, MN 55905, USA Phone: +1-507-284-8728 Fax: +1-507-284-0745 Email: [email protected] The authors declare no potential conflicts of interest. 1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 4, 2018; DOI: 10.1158/1078-0432.CCR-17-3008 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Gene Set Size Count Z-Score P-Value Q-Value List of Genes
    Supplementary Data 2-1 Results from competitive pathway enrichment analysis based on genome-wide summary-level data of hsGWAS. Gene Set Size Count z-score p-value q-value List of Genes KEGG_ALLOGRAFT_ 38 36 12.6476 0.00E+00 0.00E+00 HLA-DRB5(4.11028); IL2(3.62922); HLA-E(3.27708); HLA-G(3.2749); HLA- REJECTION DQA2(3.16347); HLA-DRA(3.14994); HLA-DOB(3.11438); HLA-DMB(3.09917); HLA-DMA(3.09615); TNF(3.09414); HLA-DPB1(3.03922); HLA-DPA1(3.0355); HLA-A(3.02312); HLA-C(2.98835); HLA-DQB1(2.97025); HLA-B(2.95626); HLA- DQA1(2.94591); HLA-F(2.83254); HLA-DRB1(2.76738); HLA-DOA(2.72508); IFNG(1.74523); PRF1(1.46483); FASLG(1.10083); FAS(0.923795); HLA- DRB3(0.760622); CD80(0.436654); IL4(0.324564); CD40(0.271072); HLA- DRB4(0.0708609); IL12A(0.0685942); IL5(0.0659333); CD86(0.049911); CD28(- 0.16103); IL10(-0.165903); IL12B(-0.245281); GZMB(-0.268581); KEGG_GRAFT_VERSUS_HOS 42 37 12.6129 0.00E+00 0.00E+00 HLA-DRB5(4.11028); IL2(3.62922); HLA-E(3.27708); HLA-G(3.2749); HLA- T_DISEASE DQA2(3.16347); HLA-DRA(3.14994); HLA-DOB(3.11438); HLA-DMB(3.09917); HLA-DMA(3.09615); TNF(3.09414); HLA-DPB1(3.03922); HLA-DPA1(3.0355); HLA-A(3.02312); HLA-C(2.98835); HLA-DQB1(2.97025); HLA-B(2.95626); HLA- DQA1(2.94591); HLA-F(2.83254); HLA-DRB1(2.76738); HLA-DOA(2.72508); IL6(1.94139); IFNG(1.74523); PRF1(1.46483); FASLG(1.10083); FAS(0.923795); HLA-DRB3(0.760622); CD80(0.436654); IL1A(0.402186); KLRD1(0.29064); KIR3DL1(0.157683); HLA-DRB4(0.0708609); CD86(0.049911); CD28(-0.16103); GZMB(-0.268581); IL1B(-0.388308); KLRC1(-0.466394); KIR3DL2(-0.786806); KEGG_TYPE_I_DIABETES_ME
    [Show full text]
  • An Inflammatory Gene Signature Distinguishes Neurofibroma
    www.nature.com/scientificreports OPEN An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages Received: 26 May 2016 Accepted: 25 January 2017 from cells in the normal peripheral Published: 03 March 2017 nervous system Kwangmin Choi1, Kakajan Komurov1, Jonathan S. Fletcher1, Edwin Jousma1, Jose A. Cancelas1,2, Jianqiang Wu1 & Nancy Ratner1 Neurofibromas are benign peripheral nerve tumors driven byNF1 loss in Schwann cells (SCs). Macrophages are abundant in neurofibromas, and macrophage targeted interventions may have therapeutic potential in these tumors. We generated gene expression data from fluorescence- activated cell sorted (FACS) SCs and macrophages from wild-type and mutant nerve and neurofibroma to identify candidate pathways involved in SC-macrophage cross-talk. While in 1-month-old Nf1 mutant nerve neither SCs nor macrophages significantly differed from their normal counterparts, both macrophages and SCs showed significantly altered cytokine gene expression in neurofibromas. Computationally reconstructed SC-macrophage molecular networks were enriched for inflammation- associated pathways. We verified that neurofibroma SC conditioned medium contains macrophage chemo-attractants including colony stimulation factor 1 (CSF1). Network analysis confirmed previously implicated pathways and predict novel paracrine and autocrine loops involving cytokines, chemokines, and growth factors. Network analysis also predicted a central role for decreased type-I interferon signaling. We validated type-I interferon expression in neurofibroma by protein profiling, and show that treatment of neurofibroma-bearing mice with polyethylene glycolyated (PEGylated) type-I interferon- α2b reduces the expression of many cytokines overexpressed in neurofibroma. These studies reveal numerous potential targetable interactions between Nf1 mutant SCs and macrophages for further analyses. Neurofibromatosis type 1 (NF1) is one of the most common human monogenic disorders, affecting about 0.3% of the human population.
    [Show full text]
  • Variation in the Type I Interferon Gene Cluster on 9P21 Influences Susceptibility to Asthma and Atopy
    Genes and Immunity (2006) 7, 169–178 & 2006 Nature Publishing Group All rights reserved 1466-4879/06 $30.00 www.nature.com/gene ORIGINAL ARTICLE Variation in the type I interferon gene cluster on 9p21 influences susceptibility to asthma and atopy A Chan1,2, DL Newman1,3, AM Shon, DH Schneider, S Kuldanek and C Ober Department of Human Genetics, The University of Chicago, Chicago, IL, USA A genome-wide screen for asthma and atopy susceptibility alleles conducted in the Hutterites, a founder population of European descent, reported evidence of linkage with a short tandem repeat polymorphism (STRP) within the type I interferon (IFN) gene cluster on chromosome 9p21. The goal of this study was to identify variation within the IFN gene cluster that influences susceptibility to asthma and atopic phenotypes. We screened approximately 25 kb of sequence, including the flanking sequence of all 15 functional genes and the single coding exon in 12, in Hutterites representing different IFNA-STRP genotypes. We identified 78 polymorphisms, and genotyped 40 of these (in 14 genes) in a large Hutterite pedigree. Modest associations (0.003oPo0.05) with asthma, bronchial hyper-responsiveness (BHR), and atopy were observed with individual variants or genes, spanning the entire 400 kb region. However, pairwise combinations of haplotypes between genes showed highly significant associations with different phenotypes (Po10À5) that were localized to specific pairs of genes or regions of this cluster. These results suggest that variation in multiple genes in the type I IFN cluster on 9p22 contribute to asthma and atopy susceptibility, and that not all genes contribute equally to all phenotypes.
    [Show full text]
  • Program in Human Neutrophils Fails To
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 is online at: average * The Journal of Immunology Anaplasma phagocytophilum , 20 of which you can access for free at: 2005; 174:6364-6372; ; from submission to initial decision 4 weeks from acceptance to publication J Immunol doi: 10.4049/jimmunol.174.10.6364 http://www.jimmunol.org/content/174/10/6364 Insights into Pathogen Immune Evasion Mechanisms: Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils Dori L. Borjesson, Scott D. Kobayashi, Adeline R. Whitney, Jovanka M. Voyich, Cynthia M. Argue and Frank R. DeLeo cites 28 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2005/05/03/174.10.6364.DC1 This article http://www.jimmunol.org/content/174/10/6364.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Insights into Pathogen Immune Evasion Mechanisms: Anaplasma phagocytophilum Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils1 Dori L.
    [Show full text]
  • SUPPLEMENTARY APPENDIX Exome Sequencing Reveals Heterogeneous Clonal Dynamics in Donor Cell Myeloid Neoplasms After Stem Cell Transplantation
    SUPPLEMENTARY APPENDIX Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation Julia Suárez-González, 1,2 Juan Carlos Triviño, 3 Guiomar Bautista, 4 José Antonio García-Marco, 4 Ángela Figuera, 5 Antonio Balas, 6 José Luis Vicario, 6 Francisco José Ortuño, 7 Raúl Teruel, 7 José María Álamo, 8 Diego Carbonell, 2,9 Cristina Andrés-Zayas, 1,2 Nieves Dorado, 2,9 Gabriela Rodríguez-Macías, 9 Mi Kwon, 2,9 José Luis Díez-Martín, 2,9,10 Carolina Martínez-Laperche 2,9* and Ismael Buño 1,2,9,11* on behalf of the Spanish Group for Hematopoietic Transplantation (GETH) 1Genomics Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), Madrid; 2Gregorio Marañón Health Research Institute (IiSGM), Madrid; 3Sistemas Genómicos, Valencia; 4Department of Hematology, Puerta de Hierro General University Hospital, Madrid; 5Department of Hematology, La Princesa University Hospital, Madrid; 6Department of Histocompatibility, Madrid Blood Centre, Madrid; 7Department of Hematology and Medical Oncology Unit, IMIB-Arrixaca, Morales Meseguer General University Hospital, Murcia; 8Centro Inmunológico de Alicante - CIALAB, Alicante; 9Department of Hematology, Gregorio Marañón General University Hospital, Madrid; 10 Department of Medicine, School of Medicine, Com - plutense University of Madrid, Madrid and 11 Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain *CM-L and IB contributed equally as co-senior authors. Correspondence:
    [Show full text]
  • The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
    Published OnlineFirst March 31, 2014; DOI: 10.1158/2326-6066.CIR-13-0209 Cancer Research Article Immunology Research The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells Kutlu G. Elpek1, Viviana Cremasco1, Hua Shen4,5, Christopher J. Harvey1, Kai W. Wucherpfennig1, Daniel R. Goldstein4,5, Paul A. Monach2, and Shannon J. Turley1,3 Abstract Myeloid cells play important regulatory roles within the tumor environment by directly promoting tumor progression and modulating the function of tumor-infiltrating lymphocytes, and as such, they represent a potential therapeutic target for the treatment of cancer. Although distinct subsets of tumor-associated myeloid cells have been identified, a broader analysis of the complete myeloid cell landscape within individual tumors and also across different tumor types has been lacking. By establishing the developmental and transcriptomic signatures of infiltrating myeloid cells from multiple primary tumors, we found that tumor-associated macro- phages (TAM) and tumor-associated neutrophils (TAN), while present within all tumors analyzed, exhibited strikingly different frequencies, gene expression profiles, and functions across cancer types. We also evaluated the impact of anatomic location and circulating factors on the myeloid cell composition of tumors. The makeup of the myeloid compartment was determined by the tumor microenvironment rather than the anatomic location of tumor development or tumor-derived circulating factors. Protumorigenic and hypoxia-associated genes were enriched in TAMs and TANs compared with splenic myeloid-derived suppressor cells. Although all TANs had an altered expression pattern of secretory effector molecules, in each tumor type they exhibited a unique cytokine, chemokine, and associated receptor expression profile.
    [Show full text]
  • Interferons and Interferon Therapy
    R.Priyanka et al /J. Pharm. Sci. & Res. Vol. 6(12), 2014, 400-403 Interferons and Interferon Therapy R.Priyanka*, Muralidharan** *II Year Student BDS, Saveetha Dental College, ** Asst. Prof. Department of Microbiology, Saveetha Dental College Abstract: Interferons(IFN) are cytokines that are responsible for the activity of the immune system . They are antiviral agents. There are mainly three types of Interferons in the humans namely Interferon Alpha (IFNA), Interferon Beta (IFNB) and Interferon Gamma (IFNG). There are also synthetically available interferons for treatment of various diseases. Interferon alpha is used to treat leukemia, cancer, Kaposi’s sarcoma in relation with AIDS , multiple myeloma etc. Interferon beta is used to treat multiple sclerosis(MS) and Interferon gamma to treat chronic granulomatous disease(CGD). The route of administration is oral or parenteral in the form of injections. There are lot of precautions to be taken before the administration of the IFN as it is not tolerated by the old aged people due to the effect of the drug. Pregnant women should avoid these as it may cause complications to the fetus and the mother. The side effects caused may be flu like symptoms, head ache, joint ache, skin rashes, dryness of the mouth, dizziness, blood problems, decrease in WBC count etc. Key Words: Diseases, Interferons, Therapy, Treatment. INTRODUCTION: IFN Alpha: What are Interferons? They are mainly involved in the innate immune response Interferons are small proteins belonging to the group against viral infections. They come in 13 sub types namely cytokinins. They have effect on immune system and inhibit IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFN8, the tumor growth.
    [Show full text]
  • Gene List HTG Edgeseq Immune Response Panel
    Gene List HTG EdgeSeq Immune Response Panel A2M AGER ARAF BIRC6 CAVIN1 CD1D CDK4 COPS2 CXCL5 AAMP AGO1 ARF1 BIRC7 CAVIN2 CD2 CDK6 COPS5 CXCL6 ABCA1 AGO2 ARF5 BLK CBL CD209 CDK8 CPA3 CXCL8 ABCB1 AGT ARG1 BLNK CBLB CD22 CDK9 CPEB4 CXCL9 ABCC2 AHI1 ARHGAP30 BMP8A CCDC116 CD226 CDKAL1 CPT1A CXCR1 ABCC3 AHR ARHGEF1 BMPER CCDC60 CD24 CDKN1A CPT1B CXCR2 ABCC5 AHSA1 ARID5B BORCS5 CCDC88B CD244 CDKN1B CPT2 CXCR3 ABCC8 AHSA2P ARL3 BRAF CCL11 CD247 CDKN1C CR2 CXCR4 ABCF1 AICDA ARPC2 BRD8 CCL13 CD27 CDKN2A CRCP CXCR5 ABHD6 AIG1 ARRB2 BRF1 CCL14 CD274 CDKN2B CREB1 CXCR6 ABL1 AIM2 ASPA BRWD1 CCL15 CD276 CDKN2C CREB3 CXorf21 ACAA2 AIRE ATF1 BSN CCL16 CD28 CDKN2D CREB3L2 CYBA ACADL AKT1 ATF2 BST2 CCL17 CD33 CEACAM1 CREB3L4 CYBB ACADM AKT1S1 ATF3_activating BTC CCL18 CD34 CEACAM3 CREBBP CYC1 ACE AKT2 ATF3_repressing BTK CCL19 CD36 CEACAM4 CREM CYLD ACE2 AKT3 ATF4 BTLA CCL2 CD38 CEACAM6 CRK CYP1B1 ACIN1 ALAS1 ATF6 BTNL2 CCL20 CD3D CEACAM8 CRLF2 CYP27A1 ACKR1 ALAS2 ATG101 BUB1 CCL21 CD3E CEBPA CRLS1 CYP4A11_ ACKR2 ALOX15 ATG16L1 BUB1B CCL22 CD3G CEBPB CRP CYP4A22 ACLY ALOX5 ATG4B C19orf33 CCL23 CD4 CEBPD CRTC3 CYP51A1 ACOT1_ACOT2 ALOX5AP ATG5 C1orf53 CCL24 CD40 CEBPG CRYGD CYP7A1 ACOT13 ALPL ATG9A C1QA CCL26 CD40LG CELF1 CSF1 DAB2IP ACOX1 AMIGO3 ATM C1QB CCL27 CD44 CELF2 CSF1R DACT1 ACOX3 ANG ATP2A2 C1QBP CCL3 CD46 CENPO CSF2 DAP ACOXL ANGPT1 ATP2B4 C1QTNF6 CCL3L_family CD48 CEP250 CSF2RA DAXX ACP5 ANGPT2 ATP5F1B C1S CCL4 CD5 CEP57 CSF2RB DBP ACPP ANGPTL1 ATP6V0A1 C2 CCL5 CD52 CFB CSF3 DCLRE1B ACSL1 ANGPTL4 ATP6V0C C3 CCL7 CD55 CFD CSF3R DDAH1 ACSL3 ANK3
    [Show full text]